Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors

Inclusion Criteria: * Age:18-75 years * Pathologically diagnosed advanced (stage IV) malignant melanoma, bladder cancer or colorectal cancer with measurable lesions; * Failed in the previous standard therapy; * ECOG PS (Eastern Cooperative Oncology Group performance status) score 0-2 points; * The estimated survival period is ≥3 months; * Rehabilitate from previous therapy; * Adequate organ functions; * Patient's written informed consent; Exclusion Criteria: * Tumor emergencies; * Abnormal coagulation function; * Contagious diseases, such as HIV, HBV, HCV infection; * Mental disorders; * Concomitant tumors; * Immunological co-morbidities